Bipolar II Disorder Risk and Your Genetics

What is Bipolar II disorder genetic risk?

Bipolar II disorder genetic risk refers to the inherited component of susceptibility to developing bipolar II disorder — a mood condition characterized by recurring depressive episodes and at least one hypomanic episode. Hypomania involves elevated or irritable mood that is less severe than full mania and does not typically cause the functional disruption associated with manic episodes. Heritability estimates suggest genetics contribute substantially to who develops bipolar spectrum conditions, though most people with elevated genetic risk never develop the condition.

Bipolar II is clinically distinct from bipolar I. Where bipolar I requires at least one full manic episode, bipolar II's hypomanic episodes are shorter, less severe, and generally do not require hospitalization. Both subtypes carry substantial genetic contributions, and their genetic architectures overlap considerably — recent research suggests they share many risk loci while differing at others. Studies of bipolar genetics have typically analyzed both subtypes together; findings specific to bipolar II are a subset of this literature and continue to be refined.

Lifetime population prevalence of bipolar II is approximately 1 to 2 percent globally. Family history substantially elevates risk: having a first-degree relative with bipolar disorder is associated with an estimated tenfold increase in lifetime risk, reflecting both shared genetics and shared environment.

The genetics behind Bipolar II disorder

Genome-wide association studies of bipolar disorder have identified common genetic variants distributed across the genome, each contributing a small effect on risk. No single gene or variant accounts for bipolar disorder; the architecture is highly polygenic, with hundreds to thousands of small-effect common variants collectively contributing to the inherited component of risk.

Genome-wide signals for bipolar disorder appear near genes with functions in neuronal communication, synaptic plasticity, and cellular regulation. Among genes associated with bipolar disorder signals: GATAD2A, a transcription corepressor involved in chromatin remodeling and gene regulation; ADGRE1, an adhesion G protein-coupled receptor expressed across multiple tissues; and LPAR2, a lysophosphatidic acid receptor involved in cellular signaling pathways. The mechanisms by which common variants near these genes influence risk are not fully characterized — they reflect statistical signals pointing toward biological pathways rather than established causal mechanisms.

Bipolar disorder shares substantial genetic overlap with schizophrenia and moderate overlap with major depression. This genetic co-architecture suggests that distinct psychiatric presentations can have partly overlapping molecular substrates at the population level. Bipolar II appears to share more genetic signal with depression relative to bipolar I, while bipolar I overlaps more with schizophrenia, though these distinctions are still being characterized in the literature.

30 genome-wide significant loci associated with bipolar disorder were identified in a landmark genome-wide analysis — one of the first to map the polygenic landscape of bipolar disorder at this resolution (Stahl et al. 2019).[1]

More than 40,000 bipolar disorder cases from multiple countries were analyzed in a subsequent meta-analysis, providing new insights into the genetic biology underlying both bipolar I and bipolar II subtypes (Mullins et al. 2021).[2]

What the research says

Research base: Moderate. The genetic architecture of bipolar disorder is documented through multiple large genome-wide studies with consistent findings. For bipolar II specifically, evidence is present but less extensive; most large studies analyze bipolar I and II together, and the distinct genetic features of bipolar II are still being resolved. Polygenic risk scores for bipolar disorder are currently most useful in research rather than individual clinical use.

Stahl et al. (2019) published one of the first large systematic genome-wide analyses of bipolar disorder, identifying 30 associated loci from a discovery cohort (Stahl et al. 2019).[1] The subsequent Mullins et al. (2021) meta-analysis expanded the case count to more than 40,000, confirming the highly polygenic nature of risk and highlighting signals near genes involved in ion channel function, calcium signaling, and glutamate receptor pathways (Mullins et al. 2021).[2]

Polygenic risk scores derived from these studies can sort people into higher and lower risk groups at a population level, but individual-level accuracy is limited. Even among people in the top quintile of polygenic risk, absolute lifetime risk for bipolar disorder remains substantially below certainty, and most will not develop the condition. Environmental factors, psychosocial stress, and sleep regularity each interact with genetic background in ways that current models cannot capture from genetics alone. See our methodology page for the statistical approach ExomeDNA uses for polygenic scoring of mood-related traits.

How Bipolar II disorder genetic risk affects you

Genetic risk for bipolar II disorder is distributed across the population as a statistical spectrum. The vast majority of people — including many with above-average polygenic scores — never develop bipolar disorder. What the research documents is a statistical shift in average risk across populations, not a binary forecast of who will or will not develop the condition.

The clinically most meaningful risk indicator for bipolar disorder remains family history. Having a first-degree relative with bipolar disorder is associated with approximately tenfold higher lifetime risk compared to the general population estimate of 1 to 2 percent. Polygenic risk scores add statistical context but have not been shown to substantially improve over family-history-based risk assessment for clinical purposes.

Bipolar disorder most commonly first presents between ages 15 and 25, with adolescence and early adulthood representing the peak risk window. Environmental factors during this period — sleep disruption, substance use, psychosocial stress — interact with genetic background. Genetics establishes a statistical context; environment and development shape expression.

Working with your Bipolar II risk profile

What research supports for those with family history of bipolar disorder

Research on gene-environment interactions and mood disorder onset supports several areas where behavioral factors interact with genetic vulnerability:

• Sleep regularity is load-bearing. Irregular sleep timing is one of the most consistently documented environmental contributors to mood episode risk in people with genetic vulnerability to bipolar spectrum conditions. Consistent sleep and wake times are supported by evidence.
• Limit stimulant and heavy cannabis use. Stimulants and heavy cannabis appear to interact with genetic risk for first hypomanic or manic episodes in vulnerable individuals, particularly during adolescence and young adulthood.
• Recognize early mood patterns as clinically relevant. Hypomanic episodes can be difficult to identify from the inside. Family awareness of early-warning patterns — elevated mood, reduced sleep need, increased activity and drive — supports earlier clinical engagement.
• Standard clinical care outperforms polygenic scoring. A clinician familiar with mood disorder presentations offers context that polygenic scores alone cannot provide. For people with family history, periodic mental health evaluation during the high-risk window is more actionable than polygenic score interpretation.
• Avoid major decisions based on polygenic risk alone. The individual-level accuracy of current bipolar polygenic scores is limited. Family planning, career choices, and other significant decisions should not be driven by a polygenic risk number.

Related traits and genes

Bipolar II disorder shares genetic architecture with several mental health traits. Exploring these profiles provides a broader view of mental health genetics.

Brain & Mental Health / Mental & Cognitive:

• Schizophrenia genetic risk — shares the highest genetic overlap with bipolar disorder; distinct clinical presentations with partly shared underlying biology
• Depression genetic risk — bipolar II overlaps substantially with major depression genetics, more so than bipolar I does
• ADHD genetic risk — modest but consistent genetic overlap with bipolar spectrum conditions

Cross-category links:

• Sleep chronotype genetics — circadian rhythm regulation is a documented environmental modifier of mood episode risk
• Anxiety sensitivity genetics — genetic and phenotypic correlation with bipolar spectrum conditions in large population studies

Frequently asked questions

Is Bipolar II disorder hereditary?

Substantially, yes. Twin studies estimate heritability of bipolar disorder at 60 to 85 percent, meaning genetic differences between people explain a large share of variation in who develops bipolar spectrum conditions. Family history is a meaningful risk factor: having a first-degree relative with bipolar disorder is associated with approximately tenfold higher lifetime risk compared to the 1 to 2 percent general population baseline.

Can a DNA test tell if someone will develop Bipolar II disorder?

No. Current polygenic risk scores for bipolar disorder can place a person above or below the population average in relative genetic background, but they cannot forecast individual outcomes. Even in the highest-risk quintile of polygenic scores, the large majority of people never develop bipolar disorder. Genetic information describes statistical background — it does not determine who develops the condition.

What is a bipolar disorder polygenic risk score?

A polygenic risk score aggregates many small-effect genetic variants across the genome into a single summary of relative genetic background for a trait. For bipolar disorder, current scores explain a modest fraction of overall risk variation — valuable for research into biological pathways, but not established for individual clinical use. Most people with above-average polygenic scores will not develop bipolar disorder.

If one parent has bipolar disorder, what is the lifetime risk for a child?

Family-history-based estimates suggest approximately 10 percent lifetime risk for someone with one affected first-degree relative, compared to a 1 to 2 percent general population baseline. This is a population average that varies further based on environmental and developmental factors. Polygenic scores do not meaningfully refine this family-history-based estimate with current methods.

Are Bipolar I and Bipolar II genetically different?

Partially. Bipolar I and II share many genome-wide risk loci, supporting a substantially shared genetic basis. They also show some differences: bipolar II appears to overlap more with major depression, while bipolar I overlaps more with schizophrenia. Whether these distinctions translate into meaningfully different clinical approaches is still being characterized in the research literature.